Thumbnail Image
Item

Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry

Sokolski, Mateusz
; 
Trenson, Sander
; 
Sokolska, Justyna M.
; 
D'Amario, Domenico
; 
Meyer, Philippe
; 
Poku, Nana K.
; 
Biering-Sørensen, Tor
; 
Højbjerg Lassen, Mats C.
; 
Skaarup, Kristoffer G.
; 
Barge-Caballero, Eduardo
... show 10 more
Citations
Altmetric:
Genre
Journal article
Date
2021-09-17
Advisor
Committee member
Group
Department
Medicine
Subject
COVID-19
 SARS-CoV2
 Heart failure
 Cardiovascular disease
 Risk factors
Permanent link to this record
http://hdl.handle.net/20.500.12613/6975
Collections
COVID-19 Research
Show all metadata
Files
Thumbnail Image
Wallner-JournalArticle-2021-09.pdf
Adobe PDF, 824.96 KB
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1002/ehf2.13549
Abstract
Aims: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. Methods and results: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62–81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44–2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01–2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24–4.29], P < 0.001). Conclusions: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.
Description
Citation
Citation to related work
Wiley Open Access
Has part
ESC Heart Failure, 2021
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Embedded videos